AgingResearch.NewsJoin free

Fulvestrant

InterventionApproved 2002

2 papers1 finding

PubChemChEBIMeSH

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

About aging: trials about aging, of every trial that tests the drug for any use.

No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.

  • 1 lab in 1 country
  • 425 trials, 1 about aging, 75 with no results posted
  • Funder: Fukui Prefectural University
  • Animals2

Outcomes

1

Puerarin

downin human cells1

1 study

  1. Fulvestrant inhibits puerarin in human cells.

    “Fulvestrant, an estrogen receptor antagonist, blocked the puerarin-mediated downregulation of SMA and CNN1.”

    Cellspuerarin-mediated downregulation of SMA and CNN1skin

    Puerarin blocks the aging phenotype in human dermal fibroblasts

    PloS one22 Apr 2021

More on Puerarin

Trials

1 about aging, of 425

About aging

Approved

  • FDA Faslodex

    25 Apr 2002Disease Progression, Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, postmenopausal women

  • EMA Faslodex

    9 Mar 2004Breast Neoplasms, Disease Progression, Locally Advanced or Metastatic Breast Cancer, disease relapse, postmenopausal women

  • EMA Fulvestrant Mylan

    8 Jan 2018Breast Neoplasms, Disease Progression, Locally Advanced or Metastatic Breast Cancer, disease relapse, postmenopausal women

  • FDA Fulvestrant

    20 May 2019Disease Progression, Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, postmenopausal women

  • FDA Cligavyx

    19 Aug 2019Disease Progression, Advanced Breast Cancer, Advanced or Metastatic Breast Cancer, postmenopausal women

Repurposing

All 34

Every condition in trials

  • Hereditary Sensory and Autonomic Neuropathies

    Phase 3Terminated10 trials

  • Breast Cancer Metastatic

    Phase 3Active, not recruiting7 trials

  • Recurrence

    Phase 3Results posted5 trials

  • Breast diseases

    Phase 3Results posted4 trials

  • Neoplasms by Site

    Phase 3Results posted4 trials

  • HR+/HER2- Breast Cancer

    Phase 3Active, not recruiting3 trials

All 27

  • Locally Advanced (Inoperable) or Metastatic Breast Cancer

    Phase 3Active, not recruiting2 trials

  • Endometrial Neoplasms

    Phase 2Results posted11 trials

  • Prostatic Neoplasms

    Phase 2Results posted8 trials

  • Ovarian Epithelial Carcinoma

    Phase 2Results posted5 trials

  • Uterine Cervical Neoplasms

    Phase 2Active, not recruiting5 trials

  • Anatomic Stage IV Breast Cancer AJCC v8

    Phase 2Results posted4 trials

  • HER2-negative Breast Cancer

    Phase 2Active, not recruiting4 trials

  • Small cell lung carcinoma

    Phase 2Active, not recruiting4 trials

  • Squamous Cell Carcinoma of Head and Neck

    Phase 2Active, not recruiting4 trials

  • Anatomic Stage III Breast Cancer AJCC v8

    Phase 2Results posted3 trials

  • ER-positive Breast Cancer

    Phase 2Recruiting2 trials

  • Fallopian Tube Neoplasms

    Phase 2Recruiting2 trials

  • Male Breast Neoplasms

    Phase 2Results posted2 trials

  • Metastatic HER2-Negative Breast Carcinoma

    Phase 2Recruiting2 trials

  • Metastatic Hormone Receptor-Positive Breast Carcinoma

    Phase 2Recruiting2 trials

  • Uterine Neoplasms

    Phase 2Active, not recruiting2 trials

  • Triple Negative Breast Neoplasms

    Phase 1/2Recruiting7 trials

  • Advanced solid tumor

    Phase 1/2Recruiting4 trials

  • HR+, HER2-, Advanced Breast Cancer

    Phase 1/2Recruiting2 trials

  • Adult solid tumor

    Phase 1/2Status unknown1 trial

  • Stomach neoplasm

    Phase 1Active, not recruiting2 trials

Readouts due

Stopped

  • NCT03220178TerminatedBreast neoplasm

    Due to COVID-19 pandemic, study cannot be finished in planned timeframe.

  • NCT04031885TerminatedBreast neoplasm

    Business decision based on the inability to enroll subjects into the trial

  • NCT01633060TerminatedHereditary Sensory and Autonomic Neuropathies

    Novartis decided not to pursue further development of buparlisib program (assessment of moderate PFS benefit with know, but manageable, buparlisib profile).

  • NCT03439046TerminatedHereditary Sensory and Autonomic Neuropathies

    Novartis terminated the trial early because the collected data were sufficient to perform the analysis stated for the primary endpoint.

  • NCT05082025TerminatedOvarian neoplasm

    Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed follicular lymphoma in November 2023.

  • NCT00592007TerminatedNon small cell lung carcinoma

    Study was terminated due to slow subject accrual

All 14

  • NCT00932152TerminatedNon small cell lung carcinoma

    Poor enrollment/suspended to accrual; will close per AstraZeneca request

  • NCT01953926TerminatedNon small cell lung carcinoma

    The study was terminated to align with the sponsor's current development plans for neratinib. The decision was not based on any new efficacy or safety data for neratinib.

  • NCT00217464TerminatedProstatic Neoplasms

    Closed for futility

  • NCT05554354TerminatedAnatomic Stage IV Breast Cancer AJCC v8

    Other - slow accrual

  • NCT04899349TerminatedHyperglycemia

    Study was early terminated due to slow recruitment and emerging data showing that prophylactic use of metformin may prevent or reduce the incidence of all-grades alpelisib-related hyperglycemia. The decision was not driven by safety concerns

  • NCT00722072TerminatedMale Breast Neoplasms

    Sponsor pulled funding and low accrual

  • NCT01296555Terminatednon-Hodgkin lymphoma

    The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.

  • NCT05252416TerminatedStomach neoplasm

    This trial was terminated prior to the initiation of Phase 2 for reasons not due to safety concerns.

Development

Companies
  • AstraZenecaPhase 3locally advanced or metastatic breast cancer
  • Eli LillyPhase 3breast neoplasm, neoplasm metastasis
  • Relay TherapeuticsPhase 3PIK3CA mutation, HER2-negative Breast Cancer

Trial sponsors

Latest

Related